In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Measuring immune correlates of disease acquisition and protection in the context of a clinical
trial is a prerequisite for improved vaccine design. We analysed binding and neutralizing …

In the PREVENT-19 phase 3 trial of the NVX-CoV2373 vaccine (NCT04611802), anti-spike
binding IgG concentration (spike IgG), anti-RBD binding IgG concentration (RBD IgG), and …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

In the phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine conducted in the US, Chile,
and Peru, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% …

Background Respiratory syncytial virus (RSV) can cause serious lung infections in young
children and there is currently no available vaccine. Methods We used complementary …

In the coronavirus efficacy (COVE) phase 3 efficacy trial of the mRNA-1273 vaccine, IgG
binding antibody (bAb) concentration against Spike (BA.1 strain) and neutralizing antibody (nAb…

Supplementary Information file was supposed to contain the Statistical Analysis Plan; this
was not uploaded to ejp so was not included in the Supplementary Information file. Updated …

Astronauts undertaking long-duration space missions may be vulnerable to unique stressors
that can impact human aging. Nevertheless, few studies have examined the relationship of …

… Lin; Charlene McDanal; Amanda Eaton; Marcella Sarzotti-Kelsoe; Yiwen Lu; Chenchen
Yu; Bhavesh Borate; Lars WP van der Laan; Nima Hejazi; Chuong Huynh; Jacqueline Miller; …